The Hi's and Lo's of cytarabine in acute myeloid leukemia

Justin M. Watts, Terrence Bradley

Research output: Contribution to journalArticlepeer-review


Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.

Original languageEnglish (US)
Pages (from-to)3073-3076
Number of pages4
JournalClinical Cancer Research
Issue number13
StatePublished - Jul 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The Hi's and Lo's of cytarabine in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this